G1 Therapeutics’ (GTHX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.

Several other analysts have also issued reports on the stock. Wedbush restated an outperform rating and issued a $5.00 price target (up from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. Needham & Company LLC restated a buy rating and issued a $12.00 price target on shares of G1 Therapeutics in a research report on Wednesday, May 1st.

G1 Therapeutics Price Performance

NASDAQ:GTHX opened at $4.09 on Wednesday. G1 Therapeutics has a 1 year low of $1.08 and a 1 year high of $6.14. The firm’s fifty day simple moving average is $4.30 and its 200 day simple moving average is $3.40. The company has a current ratio of 2.94, a quick ratio of 2.55 and a debt-to-equity ratio of 1.34.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $14.48 million during the quarter, compared to analyst estimates of $15.21 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. During the same quarter in the prior year, the business earned ($0.53) earnings per share. As a group, sell-side analysts expect that G1 Therapeutics will post -0.54 earnings per share for the current fiscal year.

Institutional Trading of G1 Therapeutics

Several institutional investors have recently made changes to their positions in the business. Curi Wealth Management LLC boosted its position in shares of G1 Therapeutics by 17.8% during the 3rd quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock valued at $102,000 after acquiring an additional 10,700 shares in the last quarter. Financial Advocates Investment Management bought a new position in G1 Therapeutics during the 4th quarter valued at about $39,000. SG Americas Securities LLC bought a new position in G1 Therapeutics during the 1st quarter valued at about $58,000. Creative Financial Designs Inc. ADV lifted its holdings in G1 Therapeutics by 98.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after purchasing an additional 17,475 shares during the last quarter. Finally, Capstone Investment Advisors LLC bought a new position in G1 Therapeutics during the 4th quarter valued at about $76,000. 24.21% of the stock is currently owned by institutional investors and hedge funds.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.